Howard Hughes Medical Institute’s Vertex Pharmaceuticals VRTX Stock Holding History

Howard Hughes Medical Institute’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55	Closed	-$24.9K	–	465
2025 Q4	$24.9K	Hold	55	–	–	0.01%	94
2025 Q3	$21.5K	Hold	55	–	–	0.01%	104
2025 Q2	$24.5K	Buy	+55	New	+$25.3K	0.01%	92
2016 Q2	–	Sell	-2,000	Closed	-$159K	–	184
2016 Q1	$159K	Buy	2,000 +230	+13%	+$20.8K	0.04%	120
2015 Q4	$223K	Sell	1,770 -703	-28%	-$84.9K	0.03%	128
2015 Q3	$258K	Sell	2,473 -131	-5%	-$16.8K	0.05%	111
2015 Q2	$322K	Buy	2,604 +1,343	+107%	+$169K	0.07%	112
2015 Q1	$149K	Buy	+1,261	New	+$151K	0.02%	137

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Howard Hughes Medical Institute's VRTX Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 55 shares — an estimated $24.9K sold.

Howard Hughes Medical Institute first reported a position in VRTX in Q1 2015 and held it in 8 quarters. The position peaked at $322K in Q2 2015. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 55 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.9K.
Howard Hughes Medical Institute first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Howard Hughes Medical Institute's Vertex Pharmaceuticals position peaked at $322K in Q2 2015.
1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.